vs
Side-by-side financial comparison of Alpha Cognition Inc. (ACOG) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $2.8M, roughly 105.9× Alpha Cognition Inc.). Bio-Techne runs the higher net margin — 12.8% vs -245.5%, a 258.3% gap on every dollar of revenue.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ACOG vs TECH — Head-to-Head
Income Statement — Q4 2025 vs Q2 2026
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $295.9M |
| Net Profit | $-6.9M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -283.7% | 18.4% |
| Net Margin | -245.5% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $-0.10 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8M | $295.9M | ||
| Q3 25 | $2.8M | — | ||
| Q2 25 | $1.7M | $317.0M | ||
| Q1 25 | $2.9M | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | — | $289.5M | ||
| Q2 24 | — | $306.1M | ||
| Q1 24 | — | $303.4M |
| Q4 25 | $-6.9M | $38.0M | ||
| Q3 25 | $-1.3M | — | ||
| Q2 25 | $-10.5M | $-17.7M | ||
| Q1 25 | $-2.0M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $33.6M | ||
| Q2 24 | — | $40.6M | ||
| Q1 24 | — | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | 96.7% | 62.7% | ||
| Q1 25 | 99.6% | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -283.7% | 18.4% | ||
| Q3 25 | -187.0% | — | ||
| Q2 25 | -346.1% | -7.5% | ||
| Q1 25 | -125.9% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | -245.5% | 12.8% | ||
| Q3 25 | -46.4% | — | ||
| Q2 25 | -632.7% | -5.6% | ||
| Q1 25 | -68.5% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 13.3% | ||
| Q1 24 | — | 16.2% |
| Q4 25 | $-0.10 | $0.24 | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.65 | $-0.11 | ||
| Q1 25 | $-0.13 | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.0M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $62.5M | $2.0B |
| Total Assets | $79.7M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.0M | $172.9M | ||
| Q3 25 | $35.4M | — | ||
| Q2 25 | $39.4M | $162.2M | ||
| Q1 25 | $45.5M | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $62.5M | $2.0B | ||
| Q3 25 | $33.9M | — | ||
| Q2 25 | $31.9M | $1.9B | ||
| Q1 25 | $40.8M | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $79.7M | $2.5B | ||
| Q3 25 | $46.3M | — | ||
| Q2 25 | $45.1M | $2.6B | ||
| Q1 25 | $48.6M | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.9M | — |
| Free Cash FlowOCF − Capex | $-7.1M | — |
| FCF MarginFCF / Revenue | -252.6% | — |
| Capex IntensityCapex / Revenue | 5.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-20.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $-5.3M | — | ||
| Q2 25 | $-6.1M | $98.2M | ||
| Q1 25 | $-2.0M | $41.1M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $63.9M | ||
| Q2 24 | — | $75.5M | ||
| Q1 24 | — | $81.0M |
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-6.1M | $93.3M | ||
| Q1 25 | $-2.1M | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | -252.6% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -370.9% | 29.4% | ||
| Q1 25 | -72.0% | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 0.5% | 1.5% | ||
| Q1 25 | 2.2% | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACOG
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
